Skip to content
PICO Portalanswers from OpenAlex

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial

PaperCitations, authors & open-access status

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial is a paper indexed in PICO Portal from OpenAlex.

How many citations does Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial have?

PICO Portalcitation count

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial has 228 citations in the OpenAlex counts PICO Portal stores.

When was Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial published?

PICO Portalyear

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial has 2022 year in the PICO Portal index.

What is the open-access status of Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial?

PICO Portaloa status

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial has green oa status in the PICO Portal index.

What is the DOI of Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial?

PICO Portaldoi

The DOI for Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial is on the source record.

What is the PMID of Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial?

PICO Portalpmid

The PMID for Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial is on the source record.

What is the OpenAlex record for Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial?

PICO Portalopenalex

The OpenAlex for Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial